Electrostatically bonded polymer vesicle
    6.
    发明申请
    Electrostatically bonded polymer vesicle 有权
    静电结合聚合物囊泡

    公开(公告)号:US20090081458A1

    公开(公告)日:2009-03-26

    申请号:US11919744

    申请日:2006-04-28

    IPC分类号: B32B27/08

    摘要: The present invention discloses a vesicle which is excellent in structure stability and environmental responsiveness and also can be produced by a simple operation. More particularly, the present invention discloses a vesicle comprising a membrane formed of a first block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment, and a second block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment having an electric charge which is opposite to that of the chargeable segment of the first block copolymer.

    摘要翻译: 本发明公开了一种结构稳定性和环境响应性优异的囊泡,也可以通过简单的操作来制造。 更具体地,本发明公开了一种囊泡,其包含由含有不可充电的亲水性片段和可带电部分的第一嵌段共聚物形成的膜,以及含有不可充电亲水片段的第二嵌段共聚物和具有电荷的带电部分 其与第一嵌段共聚物的可带电段的相反。

    Electrostatically bonded polymer vesicle
    8.
    发明授权
    Electrostatically bonded polymer vesicle 有权
    静电结合聚合物囊泡

    公开(公告)号:US08304497B2

    公开(公告)日:2012-11-06

    申请号:US11919744

    申请日:2006-04-28

    IPC分类号: A61K47/30 C08L77/04

    摘要: The present invention discloses a vesicle which is excellent in structure stability and environmental responsiveness and also can be produced by a simple operation. More particularly, the present invention discloses a vesicle comprising a membrane formed of a first block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment, and a second block copolymer containing a non-chargeable hydrophilic segment and a chargeable segment having an electric charge which is opposite to that of the chargeable segment of the first block copolymer.

    摘要翻译: 本发明公开了一种结构稳定性和环境响应性优异的囊泡,也可以通过简单的操作来制造。 更具体地,本发明公开了一种囊泡,其包含由含有不可充电的亲水性片段和可带电部分的第一嵌段共聚物形成的膜,以及含有不可充电亲水片段的第二嵌段共聚物和具有电荷的带电部分 其与第一嵌段共聚物的可带电段的相反。

    Anthracycline compound derivative and pharmaceutical preparation
containing the same
    10.
    发明授权
    Anthracycline compound derivative and pharmaceutical preparation containing the same 失效
    蒽环类化合物衍生物和含有它们的药物制剂

    公开(公告)号:US6080396A

    公开(公告)日:2000-06-27

    申请号:US836965

    申请日:1997-08-18

    CPC分类号: A61K9/1075

    摘要: A dimer, trimer or tetramer of an anthracycline compound which can be obtained by directly, chemically bonding anthracycline compounds having anticancer activities to each other by an alkali treatment. A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core a dimer, trimer or tetramer of anthracycline compound alone or together with other drugs. A high molecular block copolymer-drug complex pharmaceutical preparation in which the high molecular block copolymer having a hydrophilic polymer segment and a hydrophobic polymer segment forms a micelle having the hydrophilic segment as its outer shell and contains in its hydrophobic inner core an anthracycline anticancer agent, wherein, when the pharmaceutical preparation is intravenously administered to a CDF1 mouse, the amount of the anthracycline anticancer agent in 1 ml of the mouse blood plasma after 1 hour of its administration becomes 10 (% of dose/ml) or more, provided that the amount of anthracycline anticancer agent in the administered preparation is defined as 100. The aforementioned pharmaceutical preparations have high drug effects and low toxicities.

    摘要翻译: PCT No.PCT / JP96 / 02789第 371日期:1997年8月18日 102(e)日期1997年8月18日PCT提交1996年9月26日PCT公布。 公开号WO97 / 12895 日期1997年04月10日可以通过碱处理直接化学键合具有抗癌活性的蒽环类化合物而获得的蒽环类化合物的二聚体,三聚体或四聚体。 一种高分子嵌段共聚物 - 药物复合药物制剂,其中具有亲水性聚合物链段和疏水性聚合物链段的高分子嵌段共聚物形成具有亲水链段作为其外壳的胶束,并且在其疏水内核中含有二聚体,三聚体或 蒽环类化合物的四聚体单独或与其他药物一起。 一种高分子嵌段共聚物 - 药物复合药物制剂,其中具有亲水性聚合物链段和疏水性聚合物链段的高分子嵌段共聚物形成具有亲水链段作为其外壳并在其疏水内核中含有蒽环类抗癌剂的胶束, 其中,当向CDF1小鼠静脉内施用药物制剂时,在施用1小时后1ml小鼠血浆中的蒽环类抗癌剂的量为10(%/剂量)以上,条件是 给药制剂中蒽环类抗癌剂的量定义为100.上述药物制剂具有高药物作用和低毒性。